NEVRO CORP's ticker is and the CUSIP is 64157FAC7. A total of 9 filers reported holding NEVRO CORP in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $6,316,983 | +0.0% | 6,667,000 | 0.0% | 0.02% | +21.1% |
Q4 2023 | $6,316,982 | +1.5% | 6,667,000 | 0.0% | 0.02% | -32.1% |
Q3 2023 | $6,225,645 | +1.1% | 6,667,000 | 0.0% | 0.03% | -6.7% |
Q2 2023 | $6,160,308 | -1.7% | 6,667,000 | 0.0% | 0.03% | -6.2% |
Q1 2023 | $6,266,980 | +20.5% | 6,667,000 | +17.6% | 0.03% | -15.8% |
Q4 2022 | $5,199,473 | -3.1% | 5,667,000 | 0.0% | 0.04% | +18.8% |
Q3 2022 | $5,364,000 | +1.6% | 5,667,000 | 0.0% | 0.03% | +23.1% |
Q2 2022 | $5,281,000 | -83.8% | 5,667,000 | -81.2% | 0.03% | -71.1% |
Q1 2022 | $32,611,000 | -8.2% | 30,167,000 | -5.5% | 0.09% | +52.5% |
Q4 2021 | $35,522,000 | -17.6% | 31,917,000 | 0.0% | 0.06% | -30.6% |
Q3 2021 | $43,108,000 | +13.5% | 31,917,000 | +45.6% | 0.08% | -1.2% |
Q2 2021 | $37,971,000 | +149.9% | 21,917,000 | +119.2% | 0.09% | +91.1% |
Q1 2021 | $15,196,000 | – | 10,000,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 42,000,000 | $39,609,000 | 0.79% |
WOLVERINE ASSET MANAGEMENT LLC | 47,866,000 | $45,100,000 | 0.49% |
Context Capital Management, LLC | 7,689 | $7,201,000 | 0.48% |
PFM Health Sciences, LP | 9,000,000 | $8,519,000 | 0.31% |
PALISADE CAPITAL MANAGEMENT, LP | 1,534,000 | $1,446,000 | 0.04% |
CAPSTONE INVESTMENT ADVISORS, LLC | 5,667,000 | $5,364,000 | 0.03% |
Rock Springs Capital Management LP | 500,000 | $473,000 | 0.01% |
BNP PARIBAS FINANCIAL MARKETS | 28,872 | $1,345,435,000 | 0.00% |
LAZARD ASSET MANAGEMENT LLC | 0 | $946,000 | 0.00% |
BNP PARIBAS FINANCIAL MARKETS | 701,000 | $659,124,000 | 0.00% |